Trial Watch: Lenalidomide-based immunochemotherapy

Lenalidomide is a synthetic derivative of thalidomide currently approved by the US Food and Drug Administration for use in patients affected by multiple myeloma (in combination with dexamethasone) and low or intermediate-1 risk myelodysplastic syndromes that harbor 5q cytogenetic abnormalities. For...

Descripción completa

Detalles Bibliográficos
Autores principales: Semeraro, Michaela, Vacchelli, Erika, Eggermont, Alexander, Galon, Jerome, Zitvogel, Laurence, Kroemer, Guido, Galluzzi, Lorenzo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Landes Bioscience 2013
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3897503/
https://www.ncbi.nlm.nih.gov/pubmed/24482747
http://dx.doi.org/10.4161/onci.26494

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3897503/
https://www.ncbi.nlm.nih.gov/pubmed/24482747
http://dx.doi.org/10.4161/onci.26494

Ejemplares similares